LBRX (LBRX) reported D&A of $82K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

LBRX LBRX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

AlkermesALKS

$19.43M+162%

MapLight Therapeutics, Inc. MPLT

$162K-2.4%

Alto NeuroscienceANRO

$184K+7.6%

Zevra Therapeutics, Inc.ZVRA

$368K-77.7%

Opko HealthOPK

$22.2M-5.5%

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+163%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's D&A?: LBRX (LBRX) reported D&A of $82K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.